

# Saint Kitts and Nevis

## Tuberculosis profile

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	<0.01 (<0.01–<0.01)	2.5 (2.1–2.9)
Mortality (HIV+TB only)	<0.01 (0–<0.01)	0.09 (0–0.46)
Incidence (includes HIV+TB)	<0.01 (<0.01–<0.01)	5.1 (4.4–5.9)
Incidence (HIV+TB only)	0 (0–0)	0.7 (0.54–0.87)
Incidence (MDR/RR-TB)**	0 (0–0)	0.31 (0.16–0.45)

### Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0 (0–0)	<0.01 (0–<0.01)	<0.01 (0–<0.01)
Males	0 (0–0)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)
Total	0 (0–0)	<0.01 (<0.01–<0.01)	<0.01 (<0.01–<0.01)

### TB case notifications, 2015

Total cases notified	
Total new and relapse	
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	
- % pulmonary	
- % bacteriologically confirmed among pulmonary	

### Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.51 (0.4–0.64)

TB/HIV care in new and relapse TB patients, 2015	Number	(%)
Patients with known HIV-status who are HIV-positive		
- on antiretroviral therapy		

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			(–)
Estimated % of TB cases with MDR/RR-TB	2.3% (1.4–3.2)	15% (13–18)	
% notified tested for rifampicin resistance			
MDR/RR-TB cases tested for resistance to second-line drugs			
Laboratory-confirmed cases		MDR/RR-TB: , XDR-TB:	
Patients started on treatment ****		MDR/RR-TB: , XDR-TB:	

Treatment success rate and cohort size	Success	Cohort
New cases registered in 2014		
Previously treated cases registered in 2014		
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013		
XDR-TB cases started on second-line treatment in 2013		

### TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

### TB financing, 2016

National TB budget (US\$ millions)	
------------------------------------	--


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history


\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed

(Rate per 100 000 population per year)



— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence

— Notified (new and relapse)

— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New cases

— Previously treated cases

— HIV-positive — MDR/RR-TB — XDR-TB